KR20240018523A - 다이하이드로피리다진-3,5-다이온 유도체를 함유하는 제제 - Google Patents

다이하이드로피리다진-3,5-다이온 유도체를 함유하는 제제 Download PDF

Info

Publication number
KR20240018523A
KR20240018523A KR1020237045200A KR20237045200A KR20240018523A KR 20240018523 A KR20240018523 A KR 20240018523A KR 1020237045200 A KR1020237045200 A KR 1020237045200A KR 20237045200 A KR20237045200 A KR 20237045200A KR 20240018523 A KR20240018523 A KR 20240018523A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
weight
less
compound represented
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237045200A
Other languages
English (en)
Korean (ko)
Inventor
겐이치 사카이
히로마사 우치야마
도모유키 미노다
마유미 요시카와
시게모리 나쓰모토
류스케 다카노
Original Assignee
추가이 세이야쿠 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 추가이 세이야쿠 가부시키가이샤 filed Critical 추가이 세이야쿠 가부시키가이샤
Publication of KR20240018523A publication Critical patent/KR20240018523A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020237045200A 2021-06-08 2022-06-08 다이하이드로피리다진-3,5-다이온 유도체를 함유하는 제제 Pending KR20240018523A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPJP-P-2021-096206 2021-06-08
JP2021096206 2021-06-08
PCT/JP2022/023076 WO2022260064A1 (ja) 2021-06-08 2022-06-08 ジヒドロピリダジン-3,5-ジオン誘導体を含有する製剤

Publications (1)

Publication Number Publication Date
KR20240018523A true KR20240018523A (ko) 2024-02-13

Family

ID=84426023

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237045200A Pending KR20240018523A (ko) 2021-06-08 2022-06-08 다이하이드로피리다진-3,5-다이온 유도체를 함유하는 제제

Country Status (12)

Country Link
US (1) US20240293402A1 (cg-RX-API-DMAC7.html)
EP (1) EP4353233A4 (cg-RX-API-DMAC7.html)
JP (1) JPWO2022260064A1 (cg-RX-API-DMAC7.html)
KR (1) KR20240018523A (cg-RX-API-DMAC7.html)
CN (1) CN117460511A (cg-RX-API-DMAC7.html)
AU (1) AU2022288895A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023023708A2 (cg-RX-API-DMAC7.html)
CA (1) CA3221186A1 (cg-RX-API-DMAC7.html)
IL (1) IL309056A (cg-RX-API-DMAC7.html)
MX (1) MX2023014507A (cg-RX-API-DMAC7.html)
TW (1) TW202317118A (cg-RX-API-DMAC7.html)
WO (1) WO2022260064A1 (cg-RX-API-DMAC7.html)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011136269A1 (ja) 2010-04-28 2011-11-03 アステラス製薬株式会社 テトラヒドロベンゾチオフェン化合物
WO2012006475A1 (en) 2010-07-07 2012-01-12 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
WO2013062065A1 (ja) 2011-10-27 2013-05-02 アステラス製薬株式会社 アミノアルキル置換n-チエニルベンズアミド誘導体
WO2014003153A1 (ja) 2012-06-28 2014-01-03 協和発酵キリン株式会社 置換アミド化合物
WO2014142273A1 (ja) 2013-03-13 2014-09-18 中外製薬株式会社 ジヒドロピリダジン-3,5-ジオン誘導体
WO2016026822A1 (en) 2014-08-18 2016-02-25 Alkermes Pharma Ireland Limited Aripiprazole prodrug compositions
WO2016039458A1 (ja) 2014-09-12 2016-03-17 中外製薬株式会社 ナトリウム依存性リン酸トランスポーター阻害剤を含有する医薬
WO2018034883A1 (en) 2016-08-15 2018-02-22 Eli Lilly And Company Condensed thiophene derivatives useful as napi-iib inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9499553B2 (en) * 2013-03-13 2016-11-22 Chugai Seiyaku Kabushiki Kaisha Dihydropyridazine-3,5-dione derivative and pharmaceuticals containing the same
WO2019060604A1 (en) * 2017-09-20 2019-03-28 Teva Branded Pharmaceutical Products R&D, Inc. INHALABLE MEDICINE
US12097204B2 (en) * 2018-09-03 2024-09-24 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Solid pharmaceutical composition containing 1,3,5-triazine derivative or salt thereof

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011136269A1 (ja) 2010-04-28 2011-11-03 アステラス製薬株式会社 テトラヒドロベンゾチオフェン化合物
WO2012006475A1 (en) 2010-07-07 2012-01-12 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
WO2013062065A1 (ja) 2011-10-27 2013-05-02 アステラス製薬株式会社 アミノアルキル置換n-チエニルベンズアミド誘導体
WO2014003153A1 (ja) 2012-06-28 2014-01-03 協和発酵キリン株式会社 置換アミド化合物
WO2014142273A1 (ja) 2013-03-13 2014-09-18 中外製薬株式会社 ジヒドロピリダジン-3,5-ジオン誘導体
WO2016026822A1 (en) 2014-08-18 2016-02-25 Alkermes Pharma Ireland Limited Aripiprazole prodrug compositions
WO2016039458A1 (ja) 2014-09-12 2016-03-17 中外製薬株式会社 ナトリウム依存性リン酸トランスポーター阻害剤を含有する医薬
WO2018034883A1 (en) 2016-08-15 2018-02-22 Eli Lilly And Company Condensed thiophene derivatives useful as napi-iib inhibitors

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
"Chapter 1: Definition and classification of CKD" Kidney Int. Suppl., 2013, 3(1), 19-62.
Forster IC et al., Mol Aspects Med., 2013, 34(2-3), 386-395.
Hruska, KA et al., Kidney Int., 2008, 74(2), 148-157.
Lederer E et al., Eur. J. Physiol., 2019, 471(1), 137-148.
Levey, AS et al., Kidney Int., 2005, 67(6), 2089-2100.
Miyamoto, K et al., J. Pharm. Sci., 2011, 100(9), 3719-3730.
Ritter, CS et al., Clin. J.Am.Soc.Nephrol.2016, 11(6), 1088-1100.
Sabbagh, Y et al., J. Am. Soc. Nephrol., 2009, 20(11), 2348-2358.
발명추진협회 공개기보 제2017-501666

Also Published As

Publication number Publication date
CN117460511A (zh) 2024-01-26
MX2023014507A (es) 2024-01-26
EP4353233A1 (en) 2024-04-17
BR112023023708A2 (pt) 2024-01-30
AU2022288895A1 (en) 2024-01-18
US20240293402A1 (en) 2024-09-05
IL309056A (en) 2024-02-01
TW202317118A (zh) 2023-05-01
WO2022260064A1 (ja) 2022-12-15
JPWO2022260064A1 (cg-RX-API-DMAC7.html) 2022-12-15
EP4353233A4 (en) 2025-06-25
CA3221186A1 (en) 2022-12-15

Similar Documents

Publication Publication Date Title
Almansa et al. Co-Crystal of Tramadol hydrochloride–Celecoxib (CTC): a novel API–API co-crystal for the treatment of pain
JP4633469B2 (ja) 経口固形医薬
HK1213814A1 (zh) 双氯芬酸制剂和使用方法
UA59383C2 (uk) Композиція зипразидону (варіанти), спосіб лікування психозів та спосіб одержання великих кристалів зипразидону
KR20140069297A (ko) N-메틸-2-[3-((e)-2-피리딘-2-일-비닐)-1h-인다졸-6-일-설파닐]-벤즈아미드의 약학 조성물
JP4805234B2 (ja) 経口固形医薬
EP3290037A1 (en) Pharmaceutical composition for oral administration
JP7821749B2 (ja) アカラブルチニブマレイン酸塩剤形
CN120091817A (zh) 奥比塞曲匹与依折麦布组合治疗和固定剂量药物组合物
WO2016001208A1 (en) Stable pharmaceutical compositions in the form of immediate release tablets
TWI728156B (zh) 含有胺甲蝶呤之膜衣錠
WO2021216545A1 (en) Oral solid meloxicam formulations for the treatment of acute pain
EP4353233A1 (en) Preparation containing dihydropyridazine-3,5-dione derivative
HK40104119A (en) Formulation containing dihydropyridazine-3,5-dione derivative
JP7820568B2 (ja) 溶出性及び打錠性に優れた製剤
JP6112765B2 (ja) ロキソプロフェンナトリウム及びdl−メチルエフェドリン塩酸塩を含有する固形製剤
Munnangi Advancing Pharmaceutical Manufacturing: Innovative Applications of Hot Melt Extrusion for the Preparation of Drug Complexes and Fixed Dose Combination Immediate Release Formulation with Diverse Crystalline Properties
WO2017019862A1 (en) Combination formulation of laquinimod and glatiramer acetate with amino acids
HK40051811A (en) Diclofenac formulations and methods of use
Ely Extraction, Characterization, and Tablet Formulation of the Mitragyna Speciosa Kratom Plant
EP4059504A1 (en) Drug substance of lemborexant and medicinal composition comprising same
BR112015018952B1 (pt) Composições farmacêuticas contendo dexcetoprofeno e tramadol, seu método de fabricação e seu uso
CN118201934A (zh) 伊努帕地南盐酸盐、药物组合物及其使用方法
KR20160079178A (ko) 실로도신을 포함하는 고형 경구제제
JP6110589B2 (ja) ロキソプロフェンナトリウムとクレマスチンフマル酸塩を含有する固形製剤

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20231228

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250605

Comment text: Request for Examination of Application